Systemic Lupus Erythematosus

Petri, Michelle; Aringer, Martin; Ayoub, Isabelle; Almaani, Salem; Brunner, Hermine I.; Dall’Era, Maria; Jiang, Mengdi; Furie, Richard; Greco, Jessica; Goldblatt, Fiona; Huggins, Jennifer; Huizinga, T.; Isenberg, David; Li, Nicholas L.; Monahan, Rory C; Parikh, Samir; Pisetsky, David S.; Puravath, Abin P.; Rovin, Brad H.; Wallace, Daniel J.; Zhang, Xuan; Zhao, Lu

doi:10.1007/978-3-031-23488-0_12

A Clinician's Pearls &Amp; Myths in Rheumatology 2023

DOI: 10.1007/978-3-031-23488-0_12

|View full text |Cite

Systemic Lupus Erythematosus

Michelle Petri

Martin Aringer

Isabelle Ayoub

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 241 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Karmakar,

Kumar,

Prabhu

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life. Despite several attempts to comprehend the pathogenesis of SLE, knowledge about the precise molecular mechanisms underlying this disease is still lacking. The current treatment options for SLE are pragmatic and aim to develop composite biomarkers for daily practice, which necessitates the robust development of novel treatment strategies and drugs targeting specific responsive pathways. In this communication, we review and aim to explore emerging therapeutic modalities, including multiomics-based approaches, rational drug design, and CAR-T-cell-based immunotherapy, for the management of SLE.

show abstract

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Karmakar,

Kumar,

Prabhu

et al. 2024

Clin Exp Med

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Systemic Lupus Erythematosus

Cited by 1 publication

References 241 publications

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus

Contact Info

Product

Resources

About